GlassScriptPhysician profile
Bryan Paul Mcvay
NPI 1073714176
$13,984.28
in general payments reported to CMS, 2019-2025
11 companies · $9,746 in 2025
The $9,746 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $32.63 · 2022: $122 · 2023: $1,863 · 2024: $1,097 · 2025: $9,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,266 · Food and Beverage: $2,596 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,040 · Travel and Lodging: $1,796 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,266.24 |
| Food and Beverage | $2,595.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,040.00 |
| Travel and Lodging | $1,795.58 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,848.90 | 2019-2025 | |
| Pulmonx Corporation | $1,993.56 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Medtronic, INC. | $1,808.64 | 2023-2025 | Illumisite |
| Astrazeneca Pharmaceuticals LP | $135.00 | 2024 | Fasenra |
| Davol INC. | $53.33 | 2025 | Phasix Mesh |
| Erbe USA INC | $33.33 | 2025 | Cryo2 |
| Covidien LP | $32.63 | 2020 | |
| Galvanize Therapeutics, INC | $30.83 | 2025 | Aliya System |
| Abbvie INC. | $16.97 | 2025 | |
| Insmed, INC. | $16.24 | 2024 | Arikayce |
| Grifols USA, LLC | $14.85 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Mcvay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.